Lynx1 Capital Management LP
DORADO, PR · CIK 1910456 · 13F filing filed 2022-08-15
SEC-registered investment adviser since 2023 · limited partnership
- Assets managed$626.7m
- Staff5 · 4 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds2 (1 hedge) · $576.8m gross assets
- Form ADV · 2026-03-31SEC adviser record
- Legal entityLYNX1 CAPITAL MANAGEMENT LP (US)
- Kindhedge funds, private equity, futures
As an employer
- Offices in1 country
- Private fundshedge 1, private equity 1
$117.4m
reported value
+9.0% vs Q1 2022
12positions
99.1%in top 10
1 new
9 added
1 reduced
3 sold out
vs Q1 2022
This report includes the holdings of 1 other manager that shares the investment decisions:
- Lynx1 Capital Advisors LLC – reports through this filing
Shares in two reports are counted once in each security's totals.
Holdings, Q2 2022
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| BELLUS HEALTH INC NEW BLU | $26.2m22.29% | Reduced -20.0k |
| MERUS N V MRUS | $22.7m19.31% | Added +107.7k |
| KINNATE BIOPHARMA INC KNTE | $21.1m17.99% | Added +982.2k |
| ALPINE IMMUNE SCIENCES INC NVLS | $16.4m13.97% | Added +442.2k |
| CYMABAY THERAPEUTICS INC CBAY | $7.6m6.51% | Added +1.2m |
| PARDES BIOSCIENCES INC COM | $6.7m5.70% | Added +537.7k |
| PIERIS PHARMACEUTICALS INC COM | $6.0m5.14% | Added +2.1m |
| IMMUNIC INC COM | $3.8m3.26% | New |
| AEROVATE THERAPEUTICS INC COM | $3.0m2.55% | Added +124.6k |
| THESEUS PHARMACEUTICALS INC COM | $2.8m2.38% | Added +148.0k |
| PASSAGE BIO INC COM | $995.0k0.85% | Added +315.9k |
| OTONOMY INC OTIC | $62.0k0.05% | Unchanged |
Sold out since Q1 2022
| Security | Value then |
|---|---|
| TRAVERE THERAPEUTICS INC TVTX | $10.6m411.7k shares |
| IMMUNOGEN INC IMGN | $7.3m1.5m shares |
| ELEVATION ONCOLOGY INC | $25.0k10.0k shares |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| PASSAGE BIO INC 13D · filed 2026-07-02 | 21.0% |
| GH RESEARCH PLC GHRS · 13G · filed 2026-08-14 | 19.3%≈ $354.0m |
| NEUPHORIA THERAPEUTICS INC NEUP · 13D · filed 2025-12-29 | 16.3%≈ $3.8m |
| TSCAN THERAPEUTICS INC TCRX · 13G · filed 2026-08-14 | 13.1%≈ $3.4m |
| KORRO BIO INC KRRO · 13G · filed 2026-04-02 | 10.7%≈ $20.3m |
| C4 THERAPEUTICS INC CCCC · 13G · filed 2026-08-14 | 10.0%≈ $63.1m |
| CULLINAN THERAPEUTICS INC CGEM · 13G · filed 2025-11-14 | 9.8%≈ $105.0m |
| STOKE THERAPEUTICS INC STOK · 13G · filed 2026-08-14 | 6.5%≈ $132.1m |
| IBIO INC IBIO · 13G · filed 2026-08-14 | 5.4%≈ $4.9m |
| PRECISION BIOSCIENCES INC DTIL · 13G · filed 2026-07-20 | 5.4%≈ $10.9m |
| AGIOS PHARMACEUTICALS INC AGIO · 13G · filed 2026-05-06 | 5.1%≈ $111.8m |